Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Evaluation of neuroprotective effects of doxycycline in a primate model of PD
Objective: To evaluate the effects of doxycycline on the outcomes of 6-OHDA-induced Parkinson's disease in Sapajus apella monkeys. Background: Doxycycline (doxy) has been reported as…Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.
Objective: Although levodopa is the preferred medication for treating Parkinson's disease, it has a very poor brain absorption and limited oral bioavailability. The goal of…Role of Telemedicine- Versus Outpatient-Based Initiation And Management of Atkins Diet Therapy In Postmenopausal Women With Drug-Resistant Parkinson’s Disease During The COVID-19 Pandemic
Objective: To explore the satisfaction, effectiveness, and safety of online modified Atkins diet (MAD) initiation and follow-up by comparing a group of work-from-home postmenopausal women…The NINDS Approach to Therapeutic Development for Ultra-Rare Neurological Disorders, Bridging Translational and Clinical Frontiers in Gene-based Therapy
Objective: To establish an innovative process for fast and efficient pathways of delivering gene-based therapy for ultra-rare neurological disorders from the lab to the clinic…Altered gut microbiota composition and metabolism in Parkinson’s disease
Objective: To define changes in gut microbiota composition and metabolism to enable identification of novel therapeutic targets and strategies for disease modification. Background: Multiple cohort…A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.
Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment
Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism
Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…
- 1
- 2
- 3
- …
- 11
- Next Page »